Pain Management with Buprenorphine Transdermal Patches

Introduction to Buprenorphine

Buprenorphine transdermal patches are suitable for patients with stable opioid requirements, particularly valuable for patients with renal impairment, those unable to swallow, patients with poor tolerance to morphine, and those with poor compliance, as recommended by the European Society for Medical Oncology 1

Buprenorphine patches are beneficial for patients with renal impairment, as no dosage adjustment is needed, according to the European Association of Urology 1
Patients unable to swallow oral medications, those with poor tolerance to morphine, and those with poor medication compliance can benefit from buprenorphine patches, as stated by the European Society for Medical Oncology 1

The American Pain Society suggests administering buprenorphine by dividing the daily dose and administering every 6-8 hours, with a strength of evidence rated as moderate 2
The American Pain Society recommends continuing buprenorphine and adding full opioid agonist analgesics for breakthrough pain, with a strength of evidence rated as low 2
For hospitalized patients, the American Pain Society recommends converting buprenorphine to methadone at 30-40 mg/day to prevent withdrawal, with a strength of evidence rated as moderate 2
Transdermal buprenorphine is available in dosages of 5 μg/h, 10 μg/h, and 20 μg/h, with 5 μg/h being the lowest available dose recommended for opioid-naïve patients, and 20 μg/h being the maximum recommended dose due to QT prolongation concerns, as per the National Comprehensive Cancer Network guidelines 3

Inappropriate patient selection, such as using buprenorphine for patients with rapidly changing pain needs, can lead to inadequate pain management, as stated by the European Society for Medical Oncology 1
Abrupt discontinuation of buprenorphine can lead to withdrawal symptoms and increased sensitivity to full opioid agonists, according to the American College of Physicians 2
Buprenorphine can cause significant side effects, including respiratory depression, nausea, vomiting, constipation, headache, sweating, dizziness, sedation, and QT interval prolongation, with the risk increasing when combined with other CNS depressants, as reported by the Mayo Clinic Proceedings 4
Concomitant use of buprenorphine with QT-prolonging medications is contraindicated, and concomitant use with serotonergic agents may increase the risk of serotonin syndrome, as reported by the Mayo Clinic Proceedings 4
Pregnant women taking buprenorphine may experience neonatal opioid withdrawal syndrome (NOWS) in newborns, reduced fetal activity, and potential fetal growth restriction, as reported by the American Journal of Obstetrics and Gynecology 5

Buprenorphine provides comparable pain relief to transdermal fentanyl and morphine with fewer adverse events, as reported by the Clinical Infectious Diseases journal in 2017 6
86% of patients with chronic non-cancer pain experienced moderate to substantial pain relief when switched from long-term opioid therapy to buprenorphine, according to the Clinical Infectious Diseases journal in 2017 6
The American College of Physicians may recommend buprenorphine patches as a treatment option for patients with chronic pain who have not responded to other treatments, due to their unique pharmacological properties, including a ceiling effect on respiratory depression 7
The National Comprehensive Cancer Network guidelines recommend transdermal buprenorphine for chronic moderate to severe pain, including cancer-related pain 3
Buprenorphine has been added as a first-line treatment for chronic pain by the US Departments of Defense and Veterans Affairs due to its efficacy and safety profile 6

No dosage adjustments are needed in elderly patients, and it is safe in patients with renal impairment, making it a suitable option for these populations, as noted by the National Comprehensive Cancer Network 3
Patients with a history of substance use disorder require close monitoring for signs of misuse while taking buprenorphine, and patients taking buprenorphine should be monitored for respiratory depression, especially during initiation and dose adjustments, as reported by the Mayo Clinic Proceedings 4
To minimize risks associated with buprenorphine, monitoring for respiratory depression, assessing liver function, watching for signs of sedation and mental status changes, being vigilant for drug interactions, and educating patients about proper administration and potential side effects is recommended, as reported by the Mayo Clinic Proceedings 4